Title : Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.

Pub. Date : 2020 Aug

PMID : 32638093






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PURPOSE: This phase I study was conducted to evaluate the safety and pharmacokinetics of YM155, a potent, selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer (NSCLC). YM 155 epidermal growth factor receptor Homo sapiens